NAA30

Across TCGA pan-cancer cohorts, NAA30 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NAA30 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NAA30 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NAA30 expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

PDAC, LUAD, and UCEC are the cancer types where NAA30 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.451	0.977	.001	53	view →
LUAD	OS	Tertile	III,IV	0.334	0.834	.003	22	view →
UCEC	DFS	Median	All	0.939	0.778	.019	10	view →
HNSC	DFS	Median	All	0.991	0.913	.007	6	view →
GBM	DFS	Median	All	0.216	0.406	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NAA30–PDAC (DFS)

Open the PDAC breakdown →